Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)
Cooper, H.L., Healy, E., Theaker, J.M. and Friedmann, P.S. (2003) Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clinical and Experimental Dermatology, 28, (4), 366-368. (doi:10.1046/j.1365-2230.2003.01283.x).
Download
Full text not available from this repository.
Original Publication URL: http://dx.doi.org/10.1046/j.1365-2230.2003.01283.x
Description/Abstract
We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.
| Item Type: | Article |
|---|---|
| ISSNs: | 0307-6938 (print) |
| Related URLs: | |
| Subjects: | R Medicine > RL Dermatology |
| Divisions: | University Structure - Pre August 2011 > School of Medicine > Infection, Inflammation and Repair |
| Item ID: | 27003 |
| Date Deposited: | 26 Apr 2006 |
| Last Modified: | 01 Dec 2011 04:39 |
| Contributors: | Cooper, H.L. (Author) Healy, E. (Author) Theaker, J.M. (Author) Friedmann, P.S. (Author) |
| Date: | July 2003 |
| Status: | Published |
| Contact Email Address: | P.S.Friedmann@soton.ac.uk |
| URI: | http://eprints.soton.ac.uk/id/eprint/27003 |
Actions (login required)
 |
View Item |
